KIT and gastrointestinal stromal tumor: Current international guidelines recommend avapritinib primarily for patients with PDGFRA exon 18–mutant GIST, while alternative tyrosine kinase inhibitors remain preferred in KIT-mutant disease in later-line settings [57,119].